NCT01255800

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

A Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer: a Rational Anti-Cancer Stem Cell Combination.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in combination with cetuximab in patients with advanced head and neck cancer.

Detailed description

The purpose of this study is to determine the dose-limiting toxicities and the recommended dose for phase 2 evaluation of the combination of IPI-926 and cetuximab in patients with advanced head and neck cancer.

Conditions

• Recurrent Head and Neck Cancer

Interventions

Type	Name	Description
DRUG	IPI-926 and Cetuximab	* Patients will receive Cetuximab IV every week. * Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day.

Timeline

• Start date: 2011-04-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2010-12-07
• Last updated: 2014-01-31

Locations

1 site across 1 country: United States